281 related articles for article (PubMed ID: 14575419)
1. Usefulness of galectin-3 immunohistochemistry in differential diagnosis between thyroid follicular carcinoma and follicular adenoma.
Jakubiak-Wielganowicz M; Kubiak R; Sygut J; Pomorski L; Kordek R
Pol J Pathol; 2003; 54(2):111-5. PubMed ID: 14575419
[TBL] [Abstract][Full Text] [Related]
2. Galectin-3 expression in follicular tumours: an immunohistochemical study of its use as a marker of follicular carcinoma.
Ito Y; Yoshida H; Tomoda C; Miya A; Kobayashi K; Matsuzuka F; Yasuoka H; Kakudo K; Inohara H; Kuma K; Miyauchi A
Pathology; 2005 Aug; 37(4):296-8. PubMed ID: 16194828
[TBL] [Abstract][Full Text] [Related]
3. Galectin-3 is a presurgical marker of human thyroid carcinoma.
Orlandi F; Saggiorato E; Pivano G; Puligheddu B; Termine A; Cappia S; De Giuli P; Angeli A
Cancer Res; 1998 Jul; 58(14):3015-20. PubMed ID: 9679965
[TBL] [Abstract][Full Text] [Related]
4. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.
Than TH; Swethadri GK; Wong J; Ahmad T; Jamil D; Maganlal RK; Hamdi MM; Abdullah MS
Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527
[TBL] [Abstract][Full Text] [Related]
5. Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation.
Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
Hum Pathol; 2008 Nov; 39(11):1656-63. PubMed ID: 18657294
[TBL] [Abstract][Full Text] [Related]
6. Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms.
Aron M; Kapila K; Verma K
Indian J Pathol Microbiol; 2006 Jul; 49(3):376-80. PubMed ID: 17001889
[TBL] [Abstract][Full Text] [Related]
7. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms.
Inohara H; Honjo Y; Yoshii T; Akahani S; Yoshida J; Hattori K; Okamoto S; Sawada T; Raz A; Kubo T
Cancer; 1999 Jun; 85(11):2475-84. PubMed ID: 10357421
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of galectin-3 as a marker for malignancy in follicular patterned thyroid lesions.
Oestreicher-Kedem Y; Halpern M; Roizman P; Hardy B; Sulkes J; Feinmesser R; Stern Y
Head Neck; 2004 Nov; 26(11):960-6. PubMed ID: 15386597
[TBL] [Abstract][Full Text] [Related]
9. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms.
Mehrotra P; Okpokam A; Bouhaidar R; Johnson SJ; Wilson JA; Davies BR; Lennard TW
Histopathology; 2004 Nov; 45(5):493-500. PubMed ID: 15500653
[TBL] [Abstract][Full Text] [Related]
10. Analysis of P161NK4A protein expression in follicular thyroid tumors.
Ferenc T; Lewiński A; Lange D; Niewiadomska H; Sygut J; Sporny S; Jarzab B; Sałacińska-Loś E; Kulig A; Włoch J
Pol J Pathol; 2004; 55(4):143-8. PubMed ID: 15757201
[TBL] [Abstract][Full Text] [Related]
11. Immunostaining of galectin-3 and CD44v6 using fine-needle aspiration for distinguishing follicular carcinoma from adenoma.
Maruta J; Hashimoto H; Yamashita H; Yamashita H; Noguchi S
Diagn Cytopathol; 2004 Dec; 31(6):392-6. PubMed ID: 15540177
[TBL] [Abstract][Full Text] [Related]
12. Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue.
Fernández PL; Merino MJ; Gómez M; Campo E; Medina T; Castronovo V; Sanjuán X; Cardesa A; Liu FT; Sobel ME
J Pathol; 1997 Jan; 181(1):80-6. PubMed ID: 9072007
[TBL] [Abstract][Full Text] [Related]
13. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors.
Erickson LA; Jin L; Wollan PC; Thompson GB; van Heerden J; Lloyd RV
Mod Pathol; 1998 Feb; 11(2):169-74. PubMed ID: 9504687
[TBL] [Abstract][Full Text] [Related]
14. HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma.
Ito Y; Yoshida H; Tomoda C; Miya A; Kobayashi K; Matsuzuka F; Kakudo K; Kuma K; Miyauchi A
Anticancer Res; 2005; 25(1A):179-82. PubMed ID: 15816536
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of the thyroid peroxidase marker for distinguishing follicular thyroid carcinoma from follicular adenoma.
Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
Exp Oncol; 2006 Mar; 28(1):70-4. PubMed ID: 16614712
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.
de Matos PS; Ferreira AP; de Oliveira Facuri F; Assumpção LV; Metze K; Ward LS
Histopathology; 2005 Oct; 47(4):391-401. PubMed ID: 16178894
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis of nm23 protein expression in thyroid papillary carcinoma and follicular neoplasm.
Tabriz HM; Adabi Kh; Lashkari A; Heshmat R; Haghpanah V; Larijani B; Tavangar SM
Pathol Res Pract; 2009; 205(2):83-7. PubMed ID: 18996649
[TBL] [Abstract][Full Text] [Related]
18. Analysis of nm23-H1 protein immunoreactivity in follicular thyroid tumors.
Ferenc T; Lewiński A; Lange D; Niewiadomska H; Sygut J; Sporny S; Włoch J; Sałacińska-Los E; Kulig A; Jarzab B
Pol J Pathol; 2004; 55(4):149-53. PubMed ID: 15757202
[TBL] [Abstract][Full Text] [Related]
19. The use of a combination of Ki-67, Galectin-3, and PTTG can distinguish the benign and malignant thyroid tumor.
Cui W; Lu X; Zheng S; Ma Y; Liu X; Zhang W
Clin Lab; 2012; 58(5-6):419-26. PubMed ID: 22783570
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptor gamma expression in follicular-patterned thyroid lesions. Caveats for the use of immunohistochemical studies.
Gustafson KS; LiVolsi VA; Furth EE; Pasha TL; Putt ME; Baloch ZW
Am J Clin Pathol; 2003 Aug; 120(2):175-81. PubMed ID: 12931546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
